DLBCL-话题@MedSci

#DLBCL#

51篇内容 | 2752人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2181171, encodeId=405f21811e1c4, content=<a href='/topic/show?id=dfac433ed7' target=_blank style='color:#2F92EE;'>#CD47#</a> <a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a> <a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=【Clin Transl Med】赵维莅教授团队证实CD47过表达与DLBCL微环境和进展的关系, objectType=article, longId=808927, objectId=c1e680892e5d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-staff-meeting-GXNVP9J.jpg, objectUrl=/article/show_article.do?id=c1e680892e5d, replyNumber=0, likeNumber=108, createdTime=2024-01-13, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=c1e680892e5d, moduleTitle=【Clin Transl Med】赵维莅教授团队证实CD47过表达与DLBCL微环境和进展的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1e680892e5d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1360526, encodeId=8ee11360526ae, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=ESMO 2022：奥布替尼联合R-CHOP治疗既往未经治疗的non-GCB DLBCL患者的疗效和安全性, objectType=article, longId=739080, objectId=9bbfe3908038, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bbfe3908038, replyNumber=0, likeNumber=100, createdTime=2022-09-13, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bbfe3908038, moduleTitle=ESMO 2022：奥布替尼联合R-CHOP治疗既往未经治疗的non-GCB DLBCL患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9bbfe3908038)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360525, encodeId=6c2e1360525ea, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=ESMO 2022：基于机器学习预测弥漫大B细胞淋巴瘤(DLBCL)患者的生发中心、MYC/BCL2蛋白双表达状态以及MYC基因重排的情况（LYSA研究）, objectType=article, longId=739079, objectId=dbbfe390796d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbbfe390796d, replyNumber=0, likeNumber=90, createdTime=2022-09-13, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbbfe390796d, moduleTitle=ESMO 2022：基于机器学习预测弥漫大B细胞淋巴瘤(DLBCL)患者的生发中心、MYC/BCL2蛋白双表达状态以及MYC基因重排的情况（LYSA研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbbfe390796d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360524, encodeId=c7db13605249e, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=Blood Cancer J：R-CEOP是不适合蒽环类DLBCL患者一线治疗的首选？, objectType=article, longId=738648, objectId=b946e386483e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b946e386483e, replyNumber=0, likeNumber=100, createdTime=2022-09-10, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b946e386483e, moduleTitle=Blood Cancer J：R-CEOP是不适合蒽环类DLBCL患者一线治疗的首选？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b946e386483e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360523, encodeId=c48d13605236d, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=≥70岁DLBCL患者的临床特征和生存结局，来自中国多中心研究, objectType=article, longId=735555, objectId=9b73e35555dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b73e35555dd, replyNumber=0, likeNumber=75, createdTime=2022-08-12, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b73e35555dd, moduleTitle=≥70岁DLBCL患者的临床特征和生存结局，来自中国多中心研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b73e35555dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360522, encodeId=65f21360522a2, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=【Blood Adv】rrDLBCL患者的基因突变谱及对CAR-T治疗的疗效, objectType=article, longId=734616, objectId=122ee346162f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=122ee346162f, replyNumber=0, likeNumber=72, createdTime=2022-08-06, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=122ee346162f, moduleTitle=【Blood Adv】rrDLBCL患者的基因突变谱及对CAR-T治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=122ee346162f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360521, encodeId=0ead1360521b6, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=ASH 2021：二线 Axicabtagene Cilouleucel 治疗复发/难治DLBCL，疗效更佳, objectType=article, longId=292794, objectId=003b292e949c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=003b292e949c, replyNumber=0, likeNumber=87, createdTime=2021-12-28, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=003b292e949c, moduleTitle=ASH 2021：二线 Axicabtagene Cilouleucel 治疗复发/难治DLBCL，疗效更佳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=003b292e949c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360520, encodeId=56101360520ed, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=Blood Cancer J：大剂量甲氨蝶呤可有效预防DLBCL患者孤立性CNS复发, objectType=article, longId=216228, objectId=5cf7216228e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cf7216228e4, replyNumber=0, likeNumber=102, createdTime=2021-08-25, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cf7216228e4, moduleTitle=Blood Cancer J：大剂量甲氨蝶呤可有效预防DLBCL患者孤立性CNS复发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5cf7216228e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360519, encodeId=88411360519e2, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=瑞基仑赛（Relma-cel）对于R/R DLBCL患者表现出突破性疗效, objectType=article, longId=214742, objectId=fde0214e427b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fde0214e427b, replyNumber=0, likeNumber=105, createdTime=2021-07-26, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fde0214e427b, moduleTitle=瑞基仑赛（Relma-cel）对于R/R DLBCL患者表现出突破性疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fde0214e427b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360518, encodeId=87b7136051837, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=Int J Clin Oncol：tisagenlecleucel可有效且安全的治疗某些特定的日本R/R DLBCL患者, objectType=article, longId=212391, objectId=3ae121239168, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ae121239168, replyNumber=0, likeNumber=76, createdTime=2021-06-08, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ae121239168, moduleTitle=Int J Clin Oncol：tisagenlecleucel可有效且安全的治疗某些特定的日本R/R DLBCL患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ae121239168)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360517, encodeId=19fb136051eae, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=Br J Cancer：弥散性大B细胞淋巴瘤DLBCL的新型风险分层预测模型, objectType=article, longId=211832, objectId=fc31211832f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc31211832f6, replyNumber=0, likeNumber=81, createdTime=2021-05-27, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc31211832f6, moduleTitle=Br J Cancer：弥散性大B细胞淋巴瘤DLBCL的新型风险分层预测模型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc31211832f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360516, encodeId=f44a136051646, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=Lancet oncol：Loncastuximab tesirine可有效治疗复发性/难治性DLBCL！, objectType=article, longId=211283, objectId=6e722112837b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e722112837b, replyNumber=0, likeNumber=67, createdTime=2021-05-15, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e722112837b, moduleTitle=Lancet oncol：Loncastuximab tesirine可有效治疗复发性/难治性DLBCL！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e722112837b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360515, encodeId=fc251360515ac, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=J Clin Oncol：DLBCL患者诊断-治疗间隔时间越短，基础肿瘤负荷可能越高！, objectType=article, longId=210699, objectId=0bbd21069923, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bbd21069923, replyNumber=0, likeNumber=93, createdTime=2021-05-02, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bbd21069923, moduleTitle=J Clin Oncol：DLBCL患者诊断-治疗间隔时间越短，基础肿瘤负荷可能越高！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0bbd21069923)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360514, encodeId=6614136051437, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=J Clin Oncol：3期| 来那度胺联合R-CHOP方案治疗ABC型DLBCL的疗效和安全性, objectType=article, longId=210513, objectId=1f42210513fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f42210513fc, replyNumber=0, likeNumber=0, createdTime=2021-04-28, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f42210513fc, moduleTitle=J Clin Oncol：3期| 来那度胺联合R-CHOP方案治疗ABC型DLBCL的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f42210513fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360513, encodeId=85e01360513be, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=日本厚生劳动省批准CAR-T细胞疗法Breyanzi治疗DLBCL和滤泡性淋巴瘤, objectType=article, longId=209158, objectId=40ec209158b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40ec209158b9, replyNumber=0, likeNumber=93, createdTime=2021-03-31, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40ec209158b9, moduleTitle=日本厚生劳动省批准CAR-T细胞疗法Breyanzi治疗DLBCL和滤泡性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40ec209158b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360512, encodeId=9d711360512af, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=JCO：来那度胺+R-CHOP联合治疗未能显著改善ABC型DLBCL的PFS, objectType=article, longId=207552, objectId=b86b20e552cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b86b20e552cf, replyNumber=0, likeNumber=81, createdTime=2021-02-26, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b86b20e552cf, moduleTitle=JCO：来那度胺+R-CHOP联合治疗未能显著改善ABC型DLBCL的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b86b20e552cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360511, encodeId=b80c1360511fb, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=J Clin Oncol：简化版老年患者评估量表在DLBCL老年患者中的应用, objectType=article, longId=207491, objectId=1c6c20e49130, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c6c20e49130, replyNumber=0, likeNumber=92, createdTime=2021-02-24, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c6c20e49130, moduleTitle=J Clin Oncol：简化版老年患者评估量表在DLBCL老年患者中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c6c20e49130)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360510, encodeId=9f25136051070, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=J Clin Oncol：R-CHOP方案+来那度胺可进一步改善新确诊DLBCL患者预后, objectType=article, longId=207043, objectId=91d820e04381, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91d820e04381, replyNumber=0, likeNumber=82, createdTime=2021-02-12, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91d820e04381, moduleTitle=J Clin Oncol：R-CHOP方案+来那度胺可进一步改善新确诊DLBCL患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91d820e04381)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360509, encodeId=61481360509a5, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=J Clin Oncol：利妥昔单抗-miniCHOP方案额外加入来那度胺能否进一步提高DLBCL老年患者预后？, objectType=article, longId=206361, objectId=420e206361f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=420e206361f1, replyNumber=0, likeNumber=74, createdTime=2021-01-30, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=420e206361f1, moduleTitle=J Clin Oncol：利妥昔单抗-miniCHOP方案额外加入来那度胺能否进一步提高DLBCL老年患者预后？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=420e206361f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360508, encodeId=48c213605081d, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=YESCARTA在日本获批用于治疗复发难治大B细胞淋巴瘤（DLBCL）, objectType=article, longId=206207, objectId=df2920620e11, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df2920620e11, replyNumber=0, likeNumber=80, createdTime=2021-01-26, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df2920620e11, moduleTitle=YESCARTA在日本获批用于治疗复发难治大B细胞淋巴瘤（DLBCL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df2920620e11)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

DLBCL

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#CD47# #弥漫性大B细胞淋巴瘤# #DLBCL#

【Clin Transl Med】赵维莅教授团队证实CD47过表达与DLBCL微环境和进展的关系

2024-01-13发表于陕西省

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

ESMO 2022：奥布替尼联合R-CHOP治疗既往未经治疗的non-GCB DLBCL患者的疗效和安全性

2022-09-13

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

ESMO 2022：基于机器学习预测弥漫大B细胞淋巴瘤(DLBCL)患者的生发中心、MYC/BCL2蛋白双表达状态以及MYC基因重排的情况（LYSA研究）

2022-09-13

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

Blood Cancer J：R-CEOP是不适合蒽环类DLBCL患者一线治疗的首选？

2022-09-10

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

≥70岁DLBCL患者的临床特征和生存结局，来自中国多中心研究

2022-08-12

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

【Blood Adv】rrDLBCL患者的基因突变谱及对CAR-T治疗的疗效

2022-08-06

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

ASH 2021：二线 Axicabtagene Cilouleucel 治疗复发/难治DLBCL，疗效更佳

2021-12-28

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

Blood Cancer J：大剂量甲氨蝶呤可有效预防DLBCL患者孤立性CNS复发

2021-08-25

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

瑞基仑赛（Relma-cel）对于R/R DLBCL患者表现出突破性疗效

2021-07-26

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

Int J Clin Oncol：tisagenlecleucel可有效且安全的治疗某些特定的日本R/R DLBCL患者

2021-06-08

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

Br J Cancer：弥散性大B细胞淋巴瘤DLBCL的新型风险分层预测模型

2021-05-27

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

Lancet oncol：Loncastuximab tesirine可有效治疗复发性/难治性DLBCL！

2021-05-15

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

J Clin Oncol：DLBCL患者诊断-治疗间隔时间越短，基础肿瘤负荷可能越高！

2021-05-02

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

J Clin Oncol：3期| 来那度胺联合R-CHOP方案治疗ABC型DLBCL的疗效和安全性

2021-04-28

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

日本厚生劳动省批准CAR-T细胞疗法Breyanzi治疗DLBCL和滤泡性淋巴瘤

2021-03-31

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

JCO：来那度胺+R-CHOP联合治疗未能显著改善ABC型DLBCL的PFS

2021-02-26

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

J Clin Oncol：简化版老年患者评估量表在DLBCL老年患者中的应用

2021-02-24

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

J Clin Oncol：R-CHOP方案+来那度胺可进一步改善新确诊DLBCL患者预后

2021-02-12

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

J Clin Oncol：利妥昔单抗-miniCHOP方案额外加入来那度胺能否进一步提高DLBCL老年患者预后？

2021-01-30

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

YESCARTA在日本获批用于治疗复发难治大B细胞淋巴瘤（DLBCL）

2021-01-26

科室
- - 订阅+
  - 更多科室
工具
服务